Navigation Links
Aton Pharma Appoints Dr. Wayne Mulcahy to Vice President, Clinical Operations
Date:2/16/2010

LAWRENCEVILLE, N.J., Feb. 16 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, announced today that Wayne S. Mulcahy, Ph.D., has joined the company as Vice President, Clinical Operations. A wholly owned subsidiary of Princeton Pharma Holdings LLC, Aton is focused on the development and commercialization of unique products in ophthalmology and orphan diseases.

The company's comprehensive portfolio of well-established specialty pharmaceuticals targets cardiovascular (Mephyton®, Edecrin®, Sodium Edecrin®), metabolic (Cuprimine®, Syprine®, Demser®) and ophthalmic (Lacrisert® and the Timoptic® product line) diseases.

With more than 30 years of experience in clinical operations, Dr. Mulcahy has been responsible for the development and management of clinical programs across a range of therapeutic classes, including cardiovascular and CNS disorders, experience which is highly relevant to the clinical programs he will lead for Aton.

"Dr. Mulcahy's extensive scientific, clinical and regulatory background will provide exemplary leadership for Aton's burgeoning pipeline of development programs," said Michael G. Wells, Chief Executive Officer of Aton Pharma. "His technical acumen and strong track record of NDA submissions will help Aton fulfill its mission of bringing innovative and medically necessary medications to patients in need around the world."

Prior to joining Aton, Dr. Mulcahy served as Vice President of Research and Development at Alita Pharmaceuticals, as Vice President of Clinical Operations at the Duramed Research subsidiary of Barr Pharmaceuticals and as Senior Director of Scientific and Regulatory Affairs at Teva Pharmaceuticals North America. He began his pharmaceutical career at Merck Research Laboratories where he was awarded a Doctoral Study Fellowship. Dr. Mulcahy earned his Ph.D. in pharmacology from Temple University School of Medicine, an M.S. from Drexel University and his B.A. from Arcadia University.

About Aton Pharma, Inc.

Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global, diversified specialty pharmaceutical company providing essential treatments for under-treated diseases. Aton's mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access and availability of medically essential therapeutics. Aton's portfolio of products, with sales in over 30 countries, focuses on ophthalmic diseases and orphan conditions. For more information, see www.atonrx.com.

SOURCE Aton Pharma, Inc.

RELATED LINKS
http://www.atonrx.com

'/>"/>

SOURCE Aton Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. VPCI Pioneers Virtual GMP Consulting for FDA Pharmaceutical Manufacturers
2. International Merchant Advisors, Inc. Signs LOI to Invest in Pharmaceutical Chain
3. Albemarle(R) Announces Custom Manufacturing Alliance with PharmaCore(R)
4. Bioniche Pharma Acquires Seven New Products From GeneraMedix Inc.
5. International Merchant Advisors, Inc. Offers to Invest in Pharmaceutical Chain
6. Endo Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Financial Results on February 22, 2010
7. Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results
8. PARI Pharma Enrolls First Patient in Phase 2b Study of L-CsA
9. Creative Alliances with Nontraditional Players Increasingly Essential for Survival in Pharmaceutical Industry, New Ernst & Young Report Finds
10. Berkery Noyes Releases 2009 Pharma and Healthcare Information Merger & Acquisition Trends
11. Expanded London Genetics Web Site Emphasises Importance of Pharmacogenetics in Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Bay Area Lyme Foundation , collaborating ... for Tick Borne Illness , Harvard Medical School ... Medicine, University of California, Berkeley, and the Veterans ... finalists of Lyme Innovation , the first ... scientists, clinicians, researchers, entrepreneurs, and investors from several ...
(Date:6/24/2016)... Research and Markets has ... 2015-2025: Applications, Technologies, Forecasts" report to their ... Electronics, Smart Skin, Structural Health Monitoring, Composite Smart ... electronics involves electronic and/or electrical components and circuits ... structures such as vehicle bodies or conformally placed ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine ... Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC (SCP) ... obtaining investment capital for emerging technology companies. SCP has delivered investment events ... in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a ... cells and other difficult to transfect cells, announces its launch of the PluriQ™ ... Gene Editing System is a complete system for culturing and transfecting human ...
Breaking Medicine News(10 mins):